证券代码：688050 证券简称：爱博医疗 公告编号：2023-033 爱博诺德（北京）医疗科技股份有限公司 关于公司使用暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）于 2023 年 8 月 16 日召开第二届董事会第八次会议、第二届监事会第七次会议，审议通过了 《关于公司使用暂时闲置募集资金进行现金管理的议案》，同意公司使用额度不 超过人民币 15,000 万元的暂时闲置募集资金在确保不影响募集资金投资项目进度、 不影响公司正常生产经营及确保资金安全的情况下进行现金管理，用于购买安全 性高、流动性好的投资产品（包括但不限于保本型理财产品、结构性存款、通知 存款、定期存款、大额存单、协定存款等），在上述额度范围内，资金可以滚动 使用，使用期限自公司董事会审议通过之日起 12 个月内有效。董事会授权董事长 行使该项决策权及签署相关法律文件，包括（但不限于）选择合格的专业金融机 构、明确现金管理金额和期间、选择现金管理产品品种、签署 ...

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 证券代码：688050 证券简称：爱博医疗 公告编号：2023-039 爱博诺德（北京）医疗科技股份有限公司 关于召开 2023 年第一次临时股东大会的通知 （一） 股东大会类型和届次 2023 年第一次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2023 年 9 月 5 日 14 点 00 分 召开地点：北京市昌平区科技园区兴昌路 9 号爱博医疗公司总部 （五） 网络投票的系统、起止日期和投票时间 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 9 月 5 日 至 2023 年 9 月 5 日 股东大会召开日期：2023年9月5日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间 ...

产品名称：有晶体眼人工晶状体 申请人：爱博诺德（北京）医疗科技股份有限公司 产品管理类别：第三类 证券代码：688050 证券简称：爱博医疗 公告编号：2023-029 爱博诺德（北京）医疗科技股份有限公司 关于公司产品通过创新医疗器械特别审查程序的自愿 披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）之"有晶体 眼人工晶状体"于近日通过国家药品监督管理局医疗器械技术审评中心创新医疗 器械特别审查程序（创新审查受理号：CQTS2300159），现将相关情况公告如下： 一、产品基本信息 二、产品情况 有晶体眼人工晶状体属于屈光性人工晶状体，该产品植入眼内后可作为屈光 元件，降低/矫正近视。有晶体眼人工晶状体植入术已被验证为近视矫正安全、 有效手段，且可免除框架镜、隐形眼镜的日常摘戴困扰。此外，相对角膜激光术 而言，有晶体眼人工晶状体植入手术可逆，一定程度上可提供更优质的术后视觉 质量。目前国内有晶体眼人工晶状体产品全部依赖进口，公司的产品基于多项创 新技术，已 ...

Financial Performance - Net profit attributable to shareholders of the listed company was ¥78,398,180.86, reflecting a growth of 33.58% year-on-year [23]. - Operating income for the first quarter was ¥189,790,145.25, representing a year-on-year increase of 44.55% [23]. - Basic earnings per share were ¥0.75, an increase of 33.93% compared to the same period last year [23]. - Net profit attributable to shareholders increased by 33.58%, primarily due to revenue growth, although the growth rate was lower than that of operating revenue due to increased operating costs and reduced government subsidies compared to the previous year [27]. - Net profit attributable to shareholders after deducting non-recurring gains and losses rose by 43.88%, aligning closely with the growth rate of operating revenue [27]. - Net profit for Q1 2023 was ¥76,436,896.80, compared to ¥56,973,417.09 in Q1 2022, reflecting a growth of approximately 34.3% [37]. - Basic earnings per share for Q1 2023 were ¥0.75, an increase from ¥0.56 in Q1 2022 [38]. Revenue and Costs - Operating revenue increased by 44.55%, driven by the rapid recovery in sales of the "Punoming" series artificial lenses and "Punotong" corneal shaping lenses, along with a significant contribution of over 11% from other optical products [27]. - Total operating revenue for Q1 2023 reached ¥189,790,145.25, a significant increase from ¥131,293,097.39 in Q1 2022, representing a growth of approximately 44.4% [36]. - Total operating costs for Q1 2023 were ¥105,685,952.34, up from ¥64,270,661.60 in Q1 2022, indicating an increase of about 64.5% [36]. Research and Development - Research and development expenses totaled ¥25,064,163.49, which is 68.89% higher than the previous year, accounting for 13.21% of operating income [23]. - Total R&D investment increased by 68.89%, reflecting the company's efforts to enhance competitiveness and sustainable development capabilities [30]. - The company's research and development expenses for Q1 2023 were ¥20,281,491.30, up from ¥12,616,211.99 in Q1 2022, indicating an increase of approximately 60.5% [36]. Cash Flow and Assets - The net cash flow from operating activities was ¥27,162,135.98, showing a decrease of 33.54% compared to the previous year [23]. - Cash received from sales of goods and services in Q1 2023 amounted to ¥181,511,092.41, compared to ¥120,725,489.62 in Q1 2022, marking a growth of about 50.4% [38]. - The total assets at the end of the reporting period reached ¥2,320,453,439.44, an increase of 3.39% compared to the end of the previous year [6]. - Cash inflow from investment activities totaled CNY 515,907,634.08, significantly up from CNY 181,259,067.00, indicating a strong recovery in investment returns [40]. - The total cash and cash equivalents at the end of the period stood at CNY 298,750,468.63, down from CNY 472,871,517.38, reflecting a decrease of 36.7% [41]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,519, with the largest shareholder holding 12.93% of the shares [10]. - The total equity attributable to shareholders of the listed company was ¥1,942,598,869.87, up 4.43% from the previous year [6]. - The company reported a total of CNY 1,942,598,869.87 in equity attributable to shareholders, an increase from CNY 1,860,185,637.42 [46]. Regulatory and Market Activities - The company received regulatory approval for new products, including pre-formed aspheric intraocular lenses and a physiological saline nasal spray [12]. - The company plans to accelerate the promotion of new products and brand marketing activities to further drive revenue growth in the future [27].

2022 ANNUAL REPORT EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 三、 重大风险提示 五、 信永中和会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 公司拟以2022年度实施权益分派股权登记日登记的总股本数为基数，向全体股东每10股派发 现金红利人民币5.10元（含税），合计拟派发现金红利人民币53,640,123.12元（含税），占公司2022 年度合并报表归属于上市公司股东净利润的23.05%，较上年度公司现金分红总额增长37.84%。公 司不进行资本公积转增股本，不送红股。本事项已获公司第二届董事会第五次会议审议通过，尚 需提交公司股东大会审议。 九、 前瞻性陈述的风险声明 十、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 □适用 √不适用 目录 载有会计师事务所盖章、注册会计师签名并盖章的审计报告原件 4 / 230 | --- | --- ...

证券代码：688050 证券简称：爱博医疗 公告编号：2023-007 爱博诺德（北京）医疗科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （网址：http://roadshow.sseinfo.com） ● 会议召开方式：上证路演中心网络互动 ● 投资者可于 2023 年 4 月 19 日（星期三）至 4 月 24 日（星期一）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过爱博诺德（北京）医 疗 科 技 股 份 有 限 公 司 （ 以 下 简 称 " 爱 博 医 疗 " 或 " 公 司 " ） 邮 箱 （investors@ebmedical.com）进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 公司将于 2023 年 4 月 19 日披露公司《2022 年年度报告》及《2023 年第一季 度报告》。为便于广大投资者更全面深入地了解公司 2022 年度及 2023 年第一季 度经营成果 ...

证券代码：688050 证券简称：爱博医疗 爱博诺德（北京）医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-------------------------|-------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------| | | | | 编号： 202206 － 01 | | | 特定对象调研 | □分析师会议 □媒体采访 | | | 投资者关系活动 | | □业绩说明会 □新闻发布会 | □路演活动 | | 类别 | | □现场参观 □其他（电话会议） | | | 参与单 ...

2022 年第三季度报告 单位：元 币种：人民币 证券代码：688050 证券简称：爱博医疗 爱博诺德（北京）医疗科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 主要会计数据和财务指标 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|----------------------------------------|-----------------|---------------------------- ...

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2022, representing a year-on-year increase of 20%[8]. - The company achieved operating revenue of CNY 272,979,402.82 for the first half of 2022, representing a year-on-year increase of 32.33%[12]. - Net profit attributable to shareholders reached CNY 123,162,853.19, up 34.68% compared to the same period last year[12]. - The gross margin for the first half of 2022 was reported at 45%, an improvement from 40% in the same period last year[8]. - The company reported a significant increase in revenue, with a year-on-year growth of 25% in the first half of 2022[87]. - Total revenue for the first half of 2022 reached RMB 272.98 million, representing a year-on-year increase of 32.33% compared to RMB 206.29 million in the same period of 2021[46]. - Revenue from artificial crystalline lenses was RMB 177.58 million, accounting for 65.05% of total revenue, with a year-on-year growth of 15.10%[46]. - Revenue from orthokeratology lenses surged by 71.70% to RMB 75.93 million, increasing its revenue share to 27.82%[46]. - The company reported a net profit increase, with undistributed profits rising to ¥341,700,970.90 from ¥302,134,410.31, an increase of 13.1%[127]. Research and Development - The company is investing RMB 50 million in R&D for innovative medical technologies, aiming to introduce at least two new products by the end of 2022[8]. - The company's total R&D expenditure was CNY 31,225,600, accounting for 11.44% of operating revenue, which is a decrease of 2.09 percentage points year-on-year[13]. - Total R&D investment reached approximately ¥31.23 million, an increase of 11.88% compared to the previous year, with a significant rise in expensed R&D investment by 26.23%[37]. - The company has a strong talent pool and advanced experimental equipment in polymer material synthesis, positioning it as one of the few companies with independent material development capabilities in the ophthalmic sector[29]. - The company has developed a novel corneal reshaping lens with aspheric base arc, aimed at delaying myopia progression, and has received invention patent authorization in China and the US[26]. - The company has received regulatory approval for new products, including a multi-functional rigid contact lens care solution and an expanded range for orthokeratology lenses[15]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in sales from this region by the end of 2023[8]. - New product development includes the launch of a next-generation intraocular lens, which is expected to capture a 10% market share within the first year of release[8]. - The company is considering strategic acquisitions to enhance its market position, with a budget of $100 million allocated for potential deals[87]. - Market expansion plans include entering three new international markets by Q4 2022[88]. - The company has established a wholly-owned subsidiary, Aibo Shanghai Medical Technology Co., Ltd., to enhance coverage of southern China customers, with the project location now including Shanghai[106]. Risks and Challenges - The company has identified potential risks related to supply chain disruptions, which may impact production timelines and costs[8]. - The company faces risks related to technology updates and product upgrades, which could negatively impact operational performance if not managed properly[47]. - The company is exposed to market competition risks, particularly in the artificial crystalline lens market, which is dominated by imported products[53]. - The implementation of volume-based procurement policies poses a risk, as failure to win bids could result in loss of market share in affected provinces[56]. - Ongoing COVID-19 pandemic and natural disasters may negatively impact both domestic sales and exports, posing a risk to revenue and profitability[59]. Corporate Governance and Compliance - The company has committed to avoiding any substantial competition with its subsidiaries, ensuring no direct or indirect business activities that could conflict with its operations[90]. - The controlling shareholder has pledged to minimize related party transactions and ensure fair pricing to protect the interests of the company and its shareholders[91]. - The company will adhere to relevant laws and regulations when conducting related party transactions, ensuring transparency and compliance[91]. - The company has established strict quality control procedures across all stages of R&D, clinical trials, and production, ensuring reliable product quality[43]. - The company has implemented measures to ensure compliance with environmental regulations, with all wastewater and air emissions meeting discharge standards during the reporting period[78]. Financial Position and Assets - The company's total assets at the end of the reporting period amounted to 2,176,000,000.00 RMB, with cash and cash equivalents decreasing by 33.58% to 314,086,995.07 RMB[62]. - The accounts receivable increased by 52.27% to 103,236,151.80 RMB, attributed to revenue growth and extended payment terms for some customers[62]. - The total liabilities at the end of the reporting period were 1,000,000,000.00 RMB, with a significant increase in tax payable by 120.37% to 34,410,105.42 RMB[62]. - The company’s total equity is not explicitly stated but can be inferred from the total assets and liabilities[123]. - The company’s stock capital at the end of the reporting period was 105,176,712.00 RMB[151]. Shareholder Information - The total number of shares increased from 105,139,272 to 105,176,712 after the completion of the first vesting period of the restricted stock incentive plan[76]. - The largest shareholder, Jie Jiangbing, holds 13,594,779 shares, representing 12.93% of the total shares[114]. - The company has 4,300,000 shares held by Ningbo Meishan Free Trade Port Area Bojian Chuangzhi Investment Partnership, accounting for 4.09% of total shares[114]. - The restricted shares held by Jie Jiangbing and Bai Ying will become tradable on July 31, 2023, after a 36-month lock-up period[117]. - The company has not reported any changes in major shareholders or strategic investors during the reporting period[119].

Financial Performance - Revenue for Q1 2022 reached ¥131,293,097.39, an increase of 55.54% compared to the same period last year[2] - Net profit attributable to shareholders was ¥58,690,335.27, reflecting a growth of 63.00% year-over-year[2] - Net profit excluding non-recurring gains and losses was ¥52,203,876.14, up 65.15% from the previous year[2] - Basic earnings per share were ¥0.56, representing a 64.71% increase year-over-year[2] - Total operating revenue for Q1 2022 reached ¥131,293,097.39, a significant increase of 55.5% compared to ¥84,409,414.34 in Q1 2021[14] - Net profit for Q1 2022 was ¥56,973,417.09, up 57.6% from ¥36,133,957.99 in Q1 2021[17] - Operating profit for Q1 2022 was ¥72,819,938.17, representing a 81.6% increase from ¥40,093,593.73 in Q1 2021[16] - Basic earnings per share for Q1 2022 were ¥0.56, up from ¥0.34 in Q1 2021, reflecting a growth of 64.7%[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,091,113,769.92, a 2.13% increase from the end of the previous year[3] - As of March 31, 2022, the company's total assets amounted to approximately RMB 2.09 billion, an increase from RMB 2.05 billion at the end of 2021[11] - The total liabilities decreased to ¥288,366,805.26 in Q1 2022 from ¥307,463,789.44 in Q1 2021, a reduction of 6.4%[13] - Total equity attributable to shareholders increased to ¥1,738,177,735.85 in Q1 2022 from ¥1,673,846,060.67 in Q1 2021, an increase of 3.9%[13] Cash Flow - Operating cash flow net amount was ¥40,870,536.64, increasing by 33.95% compared to the same period last year[2] - Cash inflow from operating activities was ¥125,145,372.12 in Q1 2022, compared to ¥91,571,952.81 in Q1 2021, marking a growth of 36.7%[19] - The net cash flow from operating activities was $40,870,536.64, an increase from $30,512,472.57 in the previous year[20] - The ending balance of cash and cash equivalents was $151,480,786.20, down from $298,631,687.02 year-over-year[21] - The cash and cash equivalents decreased by $321,390,731.18 during the quarter, compared to a decrease of $238,208,326.49 in the previous year[20] Research and Development - R&D investment totaled ¥14,840,254.47, accounting for 11.30% of revenue, a decrease of 5 percentage points[3] - Research and development expenses for Q1 2022 were ¥12,616,211.99, an increase of 16.3% from ¥10,846,222.20 in Q1 2021[16] - The company has developed the "Punotong-Ximing" multifunctional rigid contact lens care solution, which has obtained a Class III medical device registration certificate and production license, and is currently in the market promotion phase[9] - The non-spherical extended depth of focus (EDoF) artificial lenses are starting clinical trials within China[9] Market and Operational Challenges - The increase in revenue was primarily driven by sales growth of the "Punoming" series artificial lenses and "Punotong" corneal reshaping lenses[5] - The company reported a significant impact on business growth due to the prolonged COVID-19 pandemic affecting patient visits for cataract and myopia treatments[8] - The company is facing delays in some R&D projects due to the pandemic's impact on operations[9] Non-Recurring Items - The company reported non-recurring gains of ¥6,486,459.13 for the period[5] - Tax expenses for Q1 2022 were ¥15,978,522.60, significantly higher than ¥3,974,396.34 in Q1 2021, reflecting an increase of 302.5%[16]